Trial Profile
A Double-blind, Placebo-controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of JNS001 in Adults With Attention-Deficit/Hyperactivity Disorder at Doses of 18 mg, 36 mg, 54 mg, or 72 mg Per Day.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Sep 2014
Price :
$35
*
At a glance
- Drugs Methylphenidate (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions; Therapeutic Use
- 22 Jun 2012 Actual patient number 253 added as reported by ClinicalTrials.gov. (Extension trial: NCT01357993)
- 22 Jun 2012 Status changed from recruiting to active no longer recruiting as reported by ClinicalTrials.gov. (Extension trial: NCT01357993)
- 22 Jun 2012 Status changed from recruiting to active no longer recruiting as reported by ClinicalTrials.gov. (Extension trial: NCT01357993)